| Basics |
CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc is engaged in research and development of biopharmaceutical products. It mainly focuses on acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs.
|
| IPO Date: |
July 1, 1996 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$29.29M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.10 | 3.82%
|
| Avg Daily Range (30 D): |
$0.07 | 3.45%
|
| Avg Daily Range (90 D): |
$0.08 | 3.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.28M |
| Avg Daily Volume (30 D): |
.01M |
| Avg Daily Volume (90 D): |
.01M |
| Trade Size |
| Avg Trade Size (Sh.): |
276 |
| Avg Trade Size (Sh.) (30 D): |
114 |
| Avg Trade Size (Sh.) (90 D): |
95 |
| Institutional Trades |
| Total Inst.Trades: |
31 |
| Avg Inst. Trade: |
$1.93M |
| Avg Inst. Trade (30 D): |
$3.75M |
| Avg Inst. Trade (90 D): |
$3.75M |
| Avg Inst. Trade Volume: |
.11M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.69M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
94.73K |
|
|
|
|
| Financials |
| |
TTM |
Q2 2022 |
Q1 2022 |
|
Basic EPS
|
$-.38
|
$-.56
|
$-.06
|
|
Diluted EPS
|
$-.38
|
$-.56
|
$-.06
|
|
Revenue
|
$ 10.21M
|
$ 8.57M
|
$ 9.06M
|
|
Gross Profit
|
$ 5.97M
|
$ 5.02M
|
$ 5.3M
|
|
Net Income / Loss
|
$ -5.02M
|
$ -7.49M
|
$ -8.4M
|
|
Operating Income / Loss
|
$ -6.35M
|
$ -7.75M
|
$ -7.29M
|
|
Cost of Revenue
|
$ 4.25M
|
$ 3.55M
|
$ 3.76M
|
|
Net Cash Flow
|
$ 18.97M
|
$ -9.52M
|
$ -9.45M
|
|
PE Ratio
|
|
|
|
| Splits |
| Jun 02, 2022:
10:1
|
| Jul 01, 2010:
11:1
|
|
